2025-05-15-Jefferies-马雷克斯集团（MRX）_2025年第一季度回顾背景趋缓但仍具建设性_10页_196kb

Marex Group (MRX) Equity Research Summary

Financial Performance & Results

• 1Q25 Earnings: Adjusted EPS of $0.90 (slightly below consensus estimate of $0.89).
  • Revenue reached $468M, exceeding estimates by $12M.
  • Strong performance from Agency & Execution (+$18M vs. est) and Market Making (+$11M vs. est), partially offset by lower Clearing revenue (-$13M vs. est).
• Segment Breakdown:
  • Clearing: Missed due to higher debt balances (SVIX of $17.1B) and lower NIM, as debt increases aim to bolster liquidity amid volatility.
  • Agency & Execution: Driven by securities revenue, contributing significantly to the revenue beat.
  • Market Making: Particularly Metals saw strong results (+$14M vs. est).
• Operating Income: $96.6M, in line with estimates despite lower operating margin (20.6% vs. estimated 21.2%).

Near-Term Outlook

• Business volumes normalized in May after April's elevated activity.
• Client balances remain strong, with modest increases in April, and no margin calls.
• Prime services may see modest growth despite the normalization of volumes.

Long-Term Thesis & Growth Drivers

• Growth Drivers: Market share gains, employee productivity improvements, and complementary acquisitions.
• Margin Expansion: Expected modest improvement driven by agency & execution segments.
• Diversified Earnings Profile: Benefits from diversified products, clients, and geographic exposure, enabling consistent ROE and earnings growth.

Valuation & Target

• Price Target: $48.10 (16% upside from current low).
• 12-Month View:
  • Base Case Target: $56 (14.6x FY26 EPS est).
  • Upside Scenario: $72 (17x FY26 EPS est, driven by accretive M&A).
  • Downside Scenario: $39 (revenue decline and lower multiples).

Risks & Catalysts

• Top Risks:
  • Sustained low volatility or bad debt increases (drag on margins).
  • Counterparty risk, especially with rising debt balances.
  • Regulatory challenges from Basel III and scrutiny of financial institutions.
• Catalysts:
  • Accretive M&A.
  • Further regulatory scrutiny easing.
  • Higher interest rates boosting revenue from debt issuance.

Sustainability & ESG

• Material Issues: Focus on systemic risk management to mitigate counterparty and settlement risks.
• Company Initiatives: DE&I programs, charity matching, and employee contributions.

Analyst Certification

• Rating: BUY (with 12-month price target at $48.10).
• Coverage: Initiated by Jefferies Equity Research, led by analysts Daniel Fannon, Junshi Wu, and Trevor Dodds involved in investment banking with the company.

Key Data Points

• Market Cap: $3.4B.
• Ticker: MRX.
• P/E Ratio: 24.8x (2023A), 15.6x (2024A).
• Segments: Clearing, Agency & Execution, Market Making, Solutions, Corporate Centre.

The report recommends Marex Group as a BUY, highlighting its diversified platform, growth potential, and ability to navigate uncertainty, though risks around counterparty and macroeconomic volatility are key considerations.